A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

Sarcoma, Ewing Clinical Trial

Official title:

The Efficacy and Safety of TK216 in Subjects With Relapsed or Refractory Ewing's Sarcoma：a Phase II Clinical Trial in China

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05046314
• Other study ID #: TK216-001
• Status: Recruiting
• Phase: Phase 2
• Start date: March 12, 2024
• Est. completion date: December 31, 2025

Study information

• Verified date: November 2023
• Source: Shanghai Pharmaceuticals Holding Co., Ltd
• Contact: Yang Yao
• Phone: 13916138801
• Email: yangyao_6[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a multicenter, single-arm, open-label Phase II clinical trial evaluating TK216 in combination with vincristine in the treatment of relapsed or refractory Ewing sarcoma (ES) including Ewing's sarcoma family tumors (ESFTs).

Description:

Ewing sarcoma is characterized by genomic rearrangements resulting in over-expression of ets family transcription factors driving tumor progression. TK216 is designed to inhibit this effect by inhibiting downstream effects of the EWS-FLI1 transcription factor. Based on USA RP2D result, designed as a single arm, multicenter open-label study，this study is the first study of TK216 in Chinese subjects with Ewing sarcoma. The study is designed to establish safety and efficacy data in combination with vincristine to assess the potential of TK216 for further development.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2025
• Est. primary completion date: September 13, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years and older

Eligibility

Inclusion Criteria:

Participants must meet all of the following inclusion criteria to be eligible for this study:

1. Willing to sign the informed consent form.

2. Participants with relapsed or refractory ES (including ESFT, except Ewing-like sarcoma) confirmed by cytohistology or molecular biology.

3. Life expectancy of at least 3 months.

4. Participants age = 14 years, regardless of gender.

5. At least one measurable lesion according to RECIST version 1.1.

6. Agree to have a central venous catheter in place prior to initiating infusion of study drug.

7. Prior radiotherapy is allowed if = 2 weeks must have elapsed for local palliative external beam radiotherapy; = 6 months must have elapsed if systemic radiotherapy, external craniospinal irradiation or > 50% pelvic radiotherapy; and = 6 weeks must have elapsed for other substantial bone marrow radiotherapy before the first dose. Participants who have received brain radiotherapy must have completed whole brain radiotherapy and/or gamma knife surgery at least 4 weeks prior to enrollment.

8. Stem Cell Transplant or Rescue without TBI:no evidence of active graft-versus-host disease and = 3 months must have elapsed since transplant.

9. Symptomatic CNS metastases must have been treated and remain stable for at least 4 weeks prior to the first dose of the study drug, or patients with asymptomatic brain metastases.

10. Adequate hematological and organ functions fulfilling the following laboratory requirements, and these results should be obtained within 7 days prior to the first dose:

11. ECOG performance score 0-2.

12. Cardiac ejection fraction = 50% or shortening fraction = 28%.

13. Eligible male and female participants of childbearing potential must consent to use reliable methods of contraception with their partners for at least 4 weeks before the start of protocol therapy, for the duration of study participation, and for at least 6 months after the last dose. Women of childbearing potential must have a negative blood pregnancy test within 7 days prior to the first dose.

14. Without any contraindication to vincristine.

Exclusion Criteria:

Participants will not be enrolled if they meet any of the following exclusion criteria:

1. Current participation in another therapeutic clinical trial.

2. Having received anti-tumor chemotherapy, targeted therapy or immunotherapy within 4 weeks prior to the first dose; having received Chinese herbal medicine or Chinese patent medicine-based therapies with definite anti-tumor indications within 3 weeks before study drug usage.

3. Having received systemic corticosteroids or other systemic immunosuppressive agents within 14 days prior to study, with the following exceptions:

1. Topical, ocular, intra-articular, intranasal, or inhaled corticosteroids with minimal systemic absorption;

2. Short-term (= 7 days), prophylactic use of corticosteroids or for the treatment of non-autoimmune diseases

4. Unresolved, > Grade 1 toxicity related to prior anti-tumor therapy prior to the study, according to the CTCAE version 5.0.

5. History of previous cancer, except squamous cell or basal -cell carcinoma of the skin or any in situ carcinoma that has been completely resected, which required therapy within the previous 3 years.

6. Any of the following within 6 months: uncontrolled congestive heart failure (NYHA III-IV); uncontrolled angina; onset of cerebrovascular event or transient ischemic attack; pulmonary embolism; deep vein thrombosis and symptomatic bradycardia that require the use of antiarrhythmic drugs.

7. History of QTc prolongation

8. History of additional risk factors for torsades de pointes

9. Use of concomitant medications that may increase or possibly increase the risk to prolong the QTc interval and/or induce torsades de pointes ventricular arrhythmia.

10. Having received surgical therapies (except diagnostic surgery, such as tumor biopsy, diagnostic puncture, etc.), including surgical and interventional therapies, within 4 weeks prior to treatment.

11. Systemic use of antibiotics for = 7 days within 4 weeks before TK216 treatment, or have fever of unknown origin (> 38.5 °C)

12. Positive test results for hepatitis B surface antigen, hepatitis C antibody and HIV antibody during screening.

13. Females who are pregnant or lactating.

14. Have taken potent inducers or inhibitors of CYP3A4, potent inhibitors of CYP2C19 within 2 weeks prior to the first dose of study drug, or substrates of CYP3A4/CPY2C19 with a narrow therapeutic window.

15. Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that may increase the risk associated with study participation or study drug management, or may interfere with the interpretation of the study results.

16. Participants who are not suitable for participating in this study due to any reason as judged by the investigator.

Related Conditions & MeSH terms

• Neuroectodermal Tumors, Primitive, Peripheral
• Sarcoma
• Sarcoma, Ewing

Intervention

Biological:
• TK216+Vincristin
TK216 was continuously administered for 14 days,then rest for 14 days. Vincristin is given before TK216 only in the first day of each cycle, the first cycle of VCR is 0.75mg/m^2 and 1.5mg/m^2 from the second cycle,every 28 days is a study cycle.

Locations

Country	Name	City	State
China	Peking University People's Hospital	Beijing	Beijing
China	Hunan Cancer Hospital	Changsha	Hunan
China	The Second Affiliated Hospital Zhejiang University School of Medicine	Hangzhou	Zhejiang
China	Shanghai Sixth People's Hospital	Shanghai	Shanghai
China	Tianjin Medical University Cancer Institude & Hospital	Tianjin	Tianjin
China	Union Hospital Tongji Medical College Huazhong University of Science and Technology	Wuhan	Hubei
China	Henan Cancer Hospital	Zhengzhou	Henan
China	Henan Provincial People's Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Pharmaceuticals Holding Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (IRC)	Determination of the Objective Response Rate of all patients by IRC	Up to 2 years after TK216 introduction
Secondary	Objective Response Rate (Investigator)	Determination of the Objective Response Rate of all patients by investigators	Up to 2 years after TK216 introduction
Secondary	Progression-free survival (PFS)	Determination of the progression-free survival of all patients	Up to 2 years after TK216 introduction
Secondary	Overall survival (OS)	Determination of the overall survival times of all patients	Up to 2 years after TK216 introduction
Secondary	Disease control rate (DCR)	Determination of the disease control rate of all patients	Up to 2 years after TK216 introduction
Secondary	Duration of remission (DOR)	Determination of the duration of remission of all patients	Up to 2 years after TK216 introduction
Secondary	Drug concentration in plasma	Determination of drug concentration in plasma of all patients	Up to 2 years after TK216 introduction
Secondary	Number of patients with adverse events	Adverse event type, incidence, duration, correlation with study drug	Up to 2 years after TK216 introduction